Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria

The low level of oxygenation within tumors is a major cause of radiation treatment failures. We theorized that anaerobic bacteria that can selectively destroy the hypoxic regions of tumors would enhance the effects of radiation. To test this hypothesis, we used spores of Clostridium novyi-NT to treat transplanted tumors in mice. The bacteria were found to markedly improve the efficacy of radiotherapy in several of the mouse models tested. Enhancement was noted with external beam radiation derived from a Cs-137 source, systemic radioimmunotherapy with an I-131-conjugated monoclonal antibody, and a previously undescribed form of experimental brachytherapy using plaques loaded with I-125 seeds. C. novyi-NT spores added little toxicity to the radiotherapeutic regimens, and the combination resulted in long-term remissions in a significant fraction of animals.

[1]  K. Kinzler,et al.  Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[3]  A. Dueñas-González,et al.  Modern management of locally advanced cervical carcinoma. , 2003, Cancer treatment reviews.

[4]  R. Weichselbaum,et al.  Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. , 2001, Seminars in radiation oncology.

[5]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[6]  R. Airley,et al.  Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Jain,et al.  Can engineered bacteria help control cancer? , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Teicher,et al.  Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. , 1995, Hematology/oncology clinics of North America.

[9]  M. Béhé,et al.  Retracted: Radioimmunotherapy of small‐volume disease of metastatic colorectal cancer , 2002, Cancer.

[10]  Louis B Harrison,et al.  Impact of tumor hypoxia and anemia on radiation therapy outcomes. , 2002, The oncologist.

[11]  A. Dicker,et al.  Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  C. Mcginn,et al.  Recent advances in the use of radiosensitizing nucleosides. , 2001, Seminars in radiation oncology.

[13]  D. Goldenberg,et al.  Colonic Tumor CEA, CSAp and MUC-1 Expression following Radioimmunotherapy or Chemotherapy , 2003, Tumor Biology.

[14]  S. Curley,et al.  Limitations of conventional doses of chemoradiation for unresectable biliary cancer , 2002 .

[15]  M. Mohiuddin,et al.  External-beam radiotherapy in the management of liver metastases. , 2002, Seminars in oncology.

[16]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.